Endeavor: Alternative Drug-Eluting Stent?

Endeavor: Alternative Drug-Eluting Stent?

0:00

Jean Fajadet The ESC heard the latest on the Endeavor stent, which elutes the sirolimus analogue ABT-578. Jean Fajadet from Toulouse told Audio Medica about the findings from ENDEAVOR II study of arou

Jean Fajadet

Jean Fajadet

The ESC heard the latest on the Endeavor stent, which elutes the sirolimus analogue ABT-578.Jean Fajadetfrom Toulouse told Audio Medica about the findings from ENDEAVOR II study of around 1200 patients.

Click here for all the interviews from ESC 2005

Related Episodes

TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent?

TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent?

Gregg Stone REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida GREGG STONE, Columbia University, New York New light has been thrown on the u

Long Term Outcomes of Drug Eluting and Bare Metal Stents in Patients Undergoing PCI

Long Term Outcomes of Drug Eluting and Bare Metal Stents in Patients Undergoing PCI

Laura Mauri Raymond Gibbons REFERENCE: Late Breaking Special Session, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida LAURA MAURI, Brigham and Woman’s Hospit

Patients with High Restenosis Risk Benefit More from Drug Eluting Stents

Patients with High Restenosis Risk Benefit More from Drug Eluting Stents

Raul Moreno REFERENCE: Abstract 3103, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria RAUL MORENO, University Hospital La Paz, Madrid Results from a large meta analysis s